Intuitive Surgical, Inc. with ticker code (ISRG) have now 23 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $460.00 and $302.00 suggesting an average Analsyt target price of $403.63. Now with the previous closing price of $370.07 and the analysts are correct then we can expect a percentage increase in value of 9.1%. The 50 day MA is $329.69 and the 200 moving average now moves to $309.70. The market cap for the company is 132.02B. The stock price for the company is currently $374.97 USD
The potential market cap would be $143,988,422,172 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 74.7, revenue per share of $20.29 and a 7.77% return on assets.
Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical system and the Ion endoluminal system. The Company’s products and related services enable physicians and healthcare providers to access minimally invasive care. The systems consist of a surgeon console or consoles, a patient-side cart, a vision system, and instruments and accessories. Its da Vinci products consist of five categories, such as da Vinci surgical systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. It also provides a suite of systems, learning, and services offerings. Its Ion endoluminal system extends its commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung. Its services include readiness support, maintenance support, perioperative consulting, customer hospital analytics, and market consulting optimization.
